相似文献
1
Bacillus Calmette Guérin in bladder cancer: is more immune stimulation better?
Transl Androl Urol. 2019 Dec;8(Suppl 5):S517-S520. doi: 10.21037/tau.2019.12.23.
2
Anti-interleukin-10R1 monoclonal antibody enhances bacillus Calmette-Guérin induced T-helper type 1 immune responses and antitumor immunity in a mouse orthotopic model of bladder cancer.
J Urol. 2012 Jun;187(6):2228-35. doi: 10.1016/j.juro.2012.01.030. Epub 2012 Apr 13.
3
Emerging Immunotherapy Options for bacillus Calmette-Guérin Unresponsive Nonmuscle Invasive Bladder Cancer.
J Urol. 2019 Dec;202(6):1111-1119. doi: 10.1097/JU.0000000000000297. Epub 2019 May 1.
4
Efficacy of bacillus Calmette-Guérin Strains for Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Network Meta-Analysis.
J Urol. 2017 Sep;198(3):503-510. doi: 10.1016/j.juro.2017.01.086. Epub 2017 Mar 10.
5
Construction of predictive models for cancer-specific survival of patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: results from a multicenter retrospective study.
Jpn J Clin Oncol. 2014 Nov;44(11):1101-8. doi: 10.1093/jjco/hyu119. Epub 2014 Aug 19.
6
FGFR3 Down-Regulation is Involved in bacillus Calmette-Guérin Induced Bladder Tumor Growth Inhibition.
J Urol. 2016 Jan;195(1):188-97. doi: 10.1016/j.juro.2015.06.093. Epub 2015 Jul 2.
7
Sequential bacillus Calmette-Guérin/Electromotive Drug Administration of Mitomycin C as the Standard Intravesical Regimen in High Risk Nonmuscle Invasive Bladder Cancer: 2-Year Outcomes.
J Urol. 2016 Jun;195(6):1697-703. doi: 10.1016/j.juro.2016.01.103. Epub 2016 Feb 2.
8
Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
J Urol. 2017 May;197(5):1189-1199. doi: 10.1016/j.juro.2016.12.090. Epub 2016 Dec 24.
9
Insignificant role of bacillus Calmette-Guérin maintenance therapy after complete transurethral resection of bladder tumor for intermediate- and high-risk non-muscle-invasive bladder cancer: Results from a randomized trial.
Int J Urol. 2016 Oct;23(10):854-860. doi: 10.1111/iju.13167. Epub 2016 Jul 15.
10
Intravesical bacillus Calmette-Guérin efficiently reduces p70S6K1 but not 4E-BP1 phosphorylation in nonmuscle invasive bladder cancer.
J Urol. 2015 Feb;193(2):682-9. doi: 10.1016/j.juro.2014.08.106. Epub 2014 Sep 6.
本文引用的文献
1
Evidence of Human Immune Responsiveness Shows the Improved Potential of a Recombinant BCG Strain for Bladder Cancer Treatment.
Front Immunol. 2019 Jun 26;10:1460. doi: 10.3389/fimmu.2019.01460. eCollection 2019.
2
BCG Therapy of Bladder Cancer Stimulates a Prolonged Release of the Chemoattractant CXCL10 (IP10) in Patient Urine.
Cancers (Basel). 2019 Jul 4;11(7):940. doi: 10.3390/cancers11070940.
3
Intravesical bacillus Calmette-Guérin for bladder cancer: are all the strains equal?
Transl Androl Urol. 2019 Feb;8(1):85-93. doi: 10.21037/tau.2018.08.19.
4
New Tuberculosis Vaccine Strategies: Taking Aim at Un-Natural Immunity.
Trends Immunol. 2018 May;39(5):419-433. doi: 10.1016/j.it.2018.01.006. Epub 2018 Feb 9.
5
Bacillus Calmette-Guérin (BCG) vaccine: A global assessment of demand and supply balance.
Vaccine. 2018 Jan 25;36(4):498-506. doi: 10.1016/j.vaccine.2017.12.010. Epub 2017 Dec 15.
6
Characterization of a human anti-tumoral NK cell population expanded after BCG treatment of leukocytes.
Oncoimmunology. 2017 Feb 21;6(4):e1293212. doi: 10.1080/2162402X.2017.1293212. eCollection 2017.
7
High baseline levels of interleukin-8 in leukocytes and urine predict tumor recurrence in non-muscle invasive bladder cancer patients receiving bacillus Calmette-Guerin therapy: A long-term survival analysis.
Oncoimmunology. 2017 Jan 3;6(2):e1265719. doi: 10.1080/2162402X.2016.1265719. eCollection 2017.
8
BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG.
Nat Rev Urol. 2017 Apr;14(4):244-255. doi: 10.1038/nrurol.2017.16. Epub 2017 Feb 21.
9
Validation of a protein panel for the noninvasive detection of recurrent non-muscle invasive bladder cancer.
Biomarkers. 2017 Nov;22(7):674-681. doi: 10.1080/1354750X.2016.1276628. Epub 2017 Jan 19.
10
Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guérin.
Eur Urol. 2016 Feb;69(2):197-200. doi: 10.1016/j.eururo.2015.06.023. Epub 2015 Jun 25.
Zotero 插件